- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Multiple Myeloma | Clinical
test
FDA Grants Breakthrough Therapy Designation to Talquetamab for R/R Myeloma
June 29, 2022
The FDA has granted breakthrough therapy designation to talquetamab for the treatment of previously-treated adult patients with relapsed or refractory multiple myeloma based on positive results from the phase 1/2 MonumenTAL-1 study.
Roundtable Discussion: Voorhees Discusses Managing Treatment in Multiple Myeloma
June 26, 2022
During a Targeted Oncology case-based roundtable event, Peter Voorhees, MD, discussed therapy options and transplant eligibility for patients with multiple myeloma.
Cilta-cel Shows Deep and Durable Responses for R/R Multiple Myeloma
June 22, 2022
Jesus G. Berdeja, MD, director of multiple myeloma research at Sarah Cannon Research Institute and hematology specialist at Tennessee Oncology, discusses the results of the CARTITUDE-1 trial for chimeric antigen receptor T-cell therapy with the newly-approved agent ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.
Dhakal Discusses Important Considerations for Treating Newly Diagnosed Multiple Myeloma
June 18, 2022
During a Targeted Oncology case-based roundtable event, Binod Dhakal, MD, MS, discussed key data related to the treatment of newly diagnosed multiple myeloma.
Ixazomib Plus Daratumumab Shows Strong Efficacy in Frail Patients With Relapsed/Refractory Myeloma
June 05, 2022
In elderly frail patients with relapsed/refractory multiple myeloma, treatment with ixazomib plus daratumumab achieved favorable response rates.
Transplant and Lenalidomide Maintenance Improves PFS in Newly Diagnosed Myeloma After RVd Treatment
June 05, 2022
At the 2022 ASCO Annual Meeting findings from the phase, 3 DETERMINATION trial showed off the survival benefit when adding autologous stem cell transplant and lenalidomide maintenance after RVd treatment for patients with newly diagnosed multiple myeloma.
Daratumumab Added to RVd Achieved MRD Negativity, PFS Improvement in Newly Diagnosed Myeloma
June 05, 2022
Among patients with newly diagnosed, transplant-eligible myeloma treated in a phase 2 study, induction and consolidation with daratumumab plus the RVd regimen outperformed RVd alone in terms of minimal residual disease and progression-free survival.
Vescio Discusses the Important Factors in Treatment Decisions in Transplant-Eligible Multiple Myeloma
June 02, 2022
During a Targeted Oncology case-based roundtable event, Robert A. Vescio, MD, discussed the results of several key trials related to new treatments for patients with transplant-eligible multiple myeloma.
Roundtable Discussion: Berdeja and Participants Cover When and How to Treat Patients With Late- Stage Multiple Myeloma
May 26, 2022
During a Targeted Oncology case-base roundtable event, Jesus G. Berdeja, MD, moderated a discussion around a 55-year-old Black man with late-stage multiple myeloma being treated in a rural community.
Emerging Treatment Options in the Multiple Myeloma Space
May 18, 2022
Paul G Richardson, MD, discusses the ways treatment approaches for patients with multiple myeloma has changed over the past few years.